Immune response modifier compounds for treatment of TH2 mediated and related diseases

   
   

Immune response modifier compounds--imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines--are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.

Los compuestos del modificante de la inmunorespuesta -- aminas del imidazoquinoline, aminas del imidazopyridine, aminas del cycloalkylimidazopyridine 6,7-fused, y aminas del imidazoquinoline 1,2-bridged -- son útiles para el tratamiento de enfermedades mediadas TH2 administrando una cantidad terapéutico eficaz de tales componen para inhibir la inmunorespuesta TH2, suprimen la inducción del cytokine IL-4/IL-5 y la eosinofília, así como realza la inmunorespuesta TH1.

 
Web www.patentalert.com

< Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists

< Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases

> Medication dosage inhaler system

> Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid

~ 00102